Supplemental Materials:

Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United States

Fuhan Yang¹, Thu N-A Tran¹, Emily Howerton¹, Maciej F Boni^{1*}, Joseph L Servadio^{1*}

¹Department of Biology and Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA, 16802, United States

*corresponding authors: Maciej F Boni (<u>mfb9@psu.edu</u>), Joseph L Servadio (jjs7684@psu.edu)

S1 Text. Estimating current and future vaccine coverages

To inform our estimates of annual vaccine coverage, we used data on COVID-19 vaccinations from CDC (21) between December 1, 2021 and November 30, 2022 (Table S3, Fig S3). In these data, the timing of individual-level booster shots is not provided, making it difficult to know exactly how many individuals in the US received at least one dose of a COVID-19 vaccine during this time period. To account for this, we generated a range of vaccine coverage estimates, based on conservative and optimistic assumptions about which fields represent duplicate doses (i.e., multiple doses were given to the same individual during our one-year period).

1. Conservative: this estimate assumes that all individuals competing their two-course series received the first dose of this series during the time period, and that all second boosters were given to individuals who received a first booster during the time period (i.e., $d_{cons} = d_{admin} - d_{series} - d_{second}$). In a population of nearly 332 million, this yields a conservative coverage estimate of 36%.

2. Optimistic: this estimate assumes that the only duplicate doses were those individuals completing their two-course series (i.e., $d_{opt} = d_{admin} - d_{series}$). This yields an optimistic coverage estimate of 49%.

Future trends of COVID-19 vaccination uptake are assumed to follow influenza vaccination. The average proportion of vaccines administered in each month was calculated, then linearly interpolated to generate weekly estimates of vaccination rates. Because the age groups (6 months -4 years-old; 5-12 years-old, 13-17 years-old, 18-49 years-old, 50-64 years-old, and 65 years-old and above) in the data are different from the model, the age-specific number of new vaccinees were calculated from the coverage rate and the US census in 2020, and were allocated to the age groups in our model under an assumption of uniformity within each of the above age brackets. The weekly relative coverage rate was calculated by dividing the coverage rate this week by the total coverage achieved in the year. The age-specific annual relative coverage rate is used as the future trend of COVID-19 vaccination coverage.

Parameter	Pre-Omicron	Omicron
Incubation period	6 days (fixed) (17)	3.42 days (41)
Infectious period	5 days (fixed) (17)	6 days (42)
Probability of hospitalization	0 (0-9 years),	0 (0.9 years),
by age	0.012 (10-19 years),	0.005 (10-19 years),
by age	0.012 (10 17 years), 0.021 (20-29 years),	0.021 (20-29 years),
	0.021 (20 2) years), 0.030 (30-39 years),	0.021(20/25) years), 0.024(30-39) years),
	0.048 (40-49 years),	0.024(30.35) years), 0.021(40-49 years),
	0.078 (50-59 years),	0.038 (50-59 years),
	0.147 (60-69 years),	0.056 (60-69 years),
	0.285 (70-79 years),	0.180 (70-79 years),
	0.314 (>= 80 years) (fitted)	0.242 (>= 80 years) (43)
	(17)	
Mean length of stay in	10.7 days (fixed) (17)	13.3 days (43)
hospital	1017 augs (1110a) (17)	10.0 4495 (10)
Probability of ICU admission	0.304 (0-9 years),	0.152 (0-9 years),
in hospital	0.293 (10-19 years),	0.1465 (10-19 years),
	0.283 (20-29 years),	0.141 (20-29 years),
	0.301 (30-39 years),	0.151 (30-39 years),
	0.463 (40-49 years),	0.232 (40-49 years),
	0.4245 (50-59 years),	0.212 (50-59 years),
	0.46 (60-69 years),	0.23 (60-69 years),
	0.484 (70-79 years),	0.242 (70-79 years),
	0.416 (>= 80 years) (fixed)	0.208 (>= 80 years) (40)
	(40)	
Probability of ventilation in	0.66 (fitted) (16)	0.238 (43)
ICU		
Probability of death in non-	0 (0-69 years) (fixed),	0 (0-69 years),
ICU hospital care	0.025 (70-79 years),	0.005 (70-79 years),
	0.050 (>= 80 years) (fitted)	0.011 (>= 80 years) (43)
$\mathbf{D}_{\mathbf{r}} = \mathbf{h} + $	(17)	0 (0 50
Probability of death outside	0 (0-59) (fixed),	0 (0-59 years),
of hospital	0.013 (60-69 years),	0.0013 (60-69 years),
	0.042 (70-79 years),	0.0061(70-79 years), 0.074 (> - 80 years) (44.45)
	0.227 (>= 80 years) (fitted)	0.074 (>= 80 years) (44,45)
	(17)	

Table S1: Updated clinical parameters for the Omicron variant. Clinical parameters retained from prior time periods have been previous published (17).

Table S2. Treatment efficacies of COVID-19 therapeutics

Treatment	Freatment Efficacy			
Nirmatrelvir/ritonavir	87.8 reduction of severity compared to	(11)		
(Paxlovid)	unvaccinated population (prospective study)			
	50% reduction in hospitalization compared to	(12)		
	a population mixed with unvaccinated (15%)			
	and vaccinated (85%) individuals			
	(retrospective study)			
Molnupiravir	29.9% reduction of hospitalization or death	(50)		
(Lagevrio)	compared to unvaccinated population			
	(prospective study)			
Remdesivir	86.8% reduction of hospitalization or death	(13)		
	compared to unvaccinated population			
	(prospective study)			
Bebtelovimab	36-40% reduction of hospitalization	(14)		
	compared to a population mixed with			
	unvaccinated and vaccinated individuals			
	(prospective study)			

Table S3: COVID-19 vaccine doses administered by age group in the United States between December 1, 2021-November 30, 2022.

	Value			
Total doses administered, d _{admin}	193M			
Total first doses administered, d _{first}	34M			
Total completed two-course series, d _{series}				
Total "additional" doses administered (non-bivalent), dadditional	73M			
Total second boosters administered (non-bivalent), dsecond				
Total bivalent boosters administered, dbivalent				

ref	Article	Duration	% immune (inf)	% immune (vax)	Location	Time	Notes
		2-4 weeks		82.8			ChAdOx1 against Delta
		25+ weeks		43.5		Nov 2020 - Jan 2022	
		20-24 weeks		none			
		2-4 weeks		65.5			ChAdOx1 against Omicron
	Andrews et al, 2022 (NEJM)	15-19 weeks		15.4	England		
		25+ weeks		8.8			mRNA-1273 against omicron
		2-4 weeks		75.1			
		25+ weeks		14.9			
(32)		2-4 weeks		62.4			BNT162b2 booster after ChAdOx1
		10+ weeks		39.6			
		2-4 weeks		70.1			mRNA-1273 booster after ChAdOx1
		5-9 weeks		60.9			IIIKNA-1275 booster after CliAdOx1
		5-9 weeks		46.7			ChAdOx1 booster after ChAdOx1
		2-4 weeks		67.2			BNT162b2 booster after BNT162b2
		10+ weeks		45.7			
		2-4 weeks		73.9			mRNA booster after BNT162b2
		5-9 weeks		64.4			
		2-4 weeks		64.9			BNT162b2 booster after mRNA-1273
		2-4 weeks		66.3			mRNA-1273 booster after mRNA-1273
(33)		4-6 months		86			

Table S4. Estimated durations of immunity following vaccination or infection from literature.

		6-8 months		79			VE of 2 doses against ED or urgent care visit against Delta
		10-12 months		66			
		4-6 month		88			VE of 3 doses against ED or urgent care visit against Delta
		4-6 month		37			
	Ferdinands	6-8 months		30			
	et al., 2022 (BMJ)	10-12 months		35	United States	Jan 2021 - Jul 2022	VE of 2 doses against ED or urgent care visit against Omicron
		12-14 months		16			
		16-18 months		22			VE of 3 doses against ED or urgent care visit against Omicron
		4-6 months		46			
		6-8 months		26			
		8+ months		17			
		5+ months		47	United States	Dec 2020 - Aug 2021	VE of fully vaccinated against infection, 12+
(34)	Tartof et al., 2021			43			VE of fully vaccinated against infection, 65+
	(Lancet)	Lancet)		53			VE of fully vaccinated against Delta
		4+ months		67			VE of fully vaccinated against non- Delta
(35)	De Giorgi et al., 2021 (JID)	11 months	63		United States	Apr 2020 - Feb 2021	Detectable neutralizing titers
(36)		4 months		71.4	International		

	Ssentongo et al., 2022 (BMCID)	5 months		21.8		Dec 2019 - Nov 2021 (published dates)	Systematic Review and meta analysis (18 articles)
		3 months	65.2			Jan 2020- Jun 2022 (publication date)	Systematic review and meta analysis (11 studies)
		12 months	24.7		-		
	-	15 months	15.5		-		studies)
(37)	Bobrovitz et al., 2023	3 months	69		International		Hybrid immunity with primary series vax
	(Lancet ID)	12 months	41.8				Hybrid immunity with primary series vax
		3 months	68.6				Hybrid immunity with booster
		6 months	46.5				Hybrid immunity with booster
(38)	Hansen et al. 2021 (Lancet)	3-6 months	80.5		Denmark	Sep - Dec 2020	Compared rates of Covid among those with and without infection before June 2020
	Nordstrom et al., 2022 (Lancet ID)	3-6 months	0.9696			March 2020 - Oct 2021	Infection vs no immunity
(39)		6-9 months	92		-		
		2+ months		45	Sweden		one dose hybrid vs natural infection only
		2+ months		56			two dose hybrid vs natural infection only




Figure S1. Model diagram. Adapted from previously published model (17). Changes made include adding a one-stage vaccine compartment (Vac), waning of infection-induced and vaccine-induced immunity, and fast recovery from infection. The green solid line indicates the vaccine-seeking behavior, while only susceptible and recovered individuals will benefit from vaccination. The green dashed line indicates the waning immunity acquired from infection or vaccination. The red solid line indicates the fast recovery of the infected individuals after successful treatment. The infected individuals with the failed treatment continue a normal progress of infection but with lower risk of hospitalization.




Figure S2. Calibrated output (red points) compared to the observed data (black line) in RI (left) and the US (right). After June 6, 2021 (grey vertical dashed line), the population mixing rates were calibrated to the hospitalized data in RI. New cases and new deaths in RI were simulated based on calibrated population mixing rates. The new cases, hospitalizations, and deaths in the US were scaled up from RI using the ratio of the total cases in different variant-dominant period between RI and the US. The scaled-up outputs for the US match the trends in the observed data.




Figure S3. Doses of COVID-19 vaccines administered in the United States, including total doses administered, number of the first and second doses of the primary two-dose series administered, non-bivalent booster doses, second non-bivalent booster doses, and bivalent booster doses. Coverage between December 1, 2021 and November 30, 2022 (vertical dashed lines) were applied to model parameterizations.




Figure S4. Coverage of Paxlovid in 50 states as of Dec 11, 2022. This is calculated as the cumulative administered courses of Paxlovid on Dec 11, 2022, divided by the number of patients from Jan 1, 2022, to Dec 11, 2022.




Figure S5. Vaccination coverage in 50 states between Dec 1, 2021, and Nov 30, 2022. Coverage is calculated as the number of administered doses of either a two-course primary series or booster divided by state-wide population (age > 6 months).




Figure S6. Weekly percentages of achieved coverage of influenza vaccination by age groups by calendar month. The trends observed were applied to COVID-19 vaccination administration in model projections.




Figure S7. Burden reduction slopes following treatment coverage under different vaccination coverages. Reductions in hospitalizations and deaths are more pronounced under low-vaccination circumstances.




Figure S8. Heatmaps of annual mortality under combinations of vaccine and treatment coverage under each transmission scenario and rate of immune waning.




Figure S9. Heatmaps of annual hospitalizations under combinations of vaccine and treatment coverage under each transmission scenario and rate of immune waning.




Figure S10. Heatmaps of annual incident cases under combinations of vaccine and treatment coverage under each transmission scenario and rate of immune waning.




Figure S11. Combinations of treatment coverage (horizontal axis) and vaccine coverage (vertical axis) that lead to COVID-19 mortality within the range of annual influenza mortality (10,000 – 50,000 deaths) as well as below or over this range. The starred point in the plots represents the current treatment and vaccine coverage in the United States.




Figure S12. Annual burden reduction between 2025 and 2033 given 50% and 88% vaccine effectiveness. The treatment coverage in the entire period is 13.7%.




Figure S13. Annual burden reduction between 2025 and 2033 given 20% probability of treatment failure. Vaccination coverage during the entire period is 49%.




Figure S14. Annual burden reduction between 2025 and 2033 given 30% and 50% risk reduction to hospitalization after failed treatment. The probability of failed treatment is 0.035. Vaccination coverage during the entire period is 49%.